Bosutinib-induced late-onset severe liver injury preceded by eosinophilia

Ann Hematol. 2022 Oct;101(10):2257-2262. doi: 10.1007/s00277-022-04945-1. Epub 2022 Aug 25.

Abstract

Tyrosine kinase inhibitors (TKIs) have dramatically changed the way chronic myeloid leukemia (CML) is treated. Although TKI therapy improves the overall survival of patients with CML, the management of various adverse events (AEs) from the therapy has become a major barrier to its adherence. Bosutinib is a second-generation TKI and an effective first-line treatment for CML. The most frequent AE is diarrhea; however, liver toxicity is also a major complication. In general, drug-induced hepatic enzyme elevation occurs within 1-2 weeks after treatment initiation. However, we noticed that, in a certain number of patients, liver injury appeared late (4-7 weeks) and was accompanied by eosinophilia. Herein, we retrospectively analyzed patients with CML treated with bosutinib at the Juntendo University School of Medicine and observed five patients with CML who developed late-onset liver injury with an elevation of the eosinophil count. In all cases, the liver enzyme level was within the normal range or grade 1 during the first 3 weeks of the bosutinib treatment and then elevated steeply thereafter. The pattern of hepatic toxicity was hepatocellular injury. In addition, all cases of eosinophilia tended to precede or coincide with an elevated liver enzyme level. Thus, the elevation of the eosinophil count may be a predictor for bosutinib-induced liver injury. Careful attention should be paid to delayed-onset hepatic injury, especially at 4-6 weeks after bosutinib initiation.

Keywords: Bosutinib; Chronic myeloid leukemia; Drug-induced liver injury; Eosinophilia; Tyrosine kinase inhibitor.

MeSH terms

  • Aniline Compounds
  • Antineoplastic Agents* / adverse effects
  • Eosinophilia* / chemically induced
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / chemically induced
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Liver
  • Nitriles
  • Protein Kinase Inhibitors / adverse effects
  • Quinolines* / adverse effects
  • Retrospective Studies

Substances

  • Aniline Compounds
  • Antineoplastic Agents
  • Nitriles
  • Protein Kinase Inhibitors
  • Quinolines
  • bosutinib